DAIICHI SANKYO sets up affiliate in Turkey
Important step in global expansion
Istanbul, May 13 DAIICHI SANKYO, one of the world’s leading research-driven pharmaceutical companies based in Japan, is establishing its own subsidiary in Turkey. The company, to be called DAIICHI SANKYO Ilaç Ticaret Ltd., Sti. will be headquartered in Istanbul and will initially focus on marketing the osteoporosis medication EVISTA® (Raloxifen).
“Entering the Turkish market represents a major step in the expansion of our global presence,” said Reinhard Bauer, CEO of DAIICHI SANKYO EUROPE. “With this decision, we are moving closer to achieving our goal of becoming one of Europe’s leading pharmaceutical companies by 2015.” Over the middle term, the company intends to significantly expand its line of medications, particularly with drugs coming from the company research pipeline to treat cardiovascular diseases. In addition, the company is interested in acquiring products and signing licensing agreements.
IMS Health, a leading international market-research institute in the pharmaceutical sector, expects Turkey to become one of the world’s top ten pharmaceutical markets by 2010: “A multinational pharmaceutical group like DAIICHI SANKYO has to be located there,” Bauer said.
The affiliate in Turkey will be strategically managed from Germany, where the European headquarters of the Japanese pharmaceutical company is located. The Munich office directs the company’s affiliates in 10 other European countries where the company has had subsidiaries for a long period of time. These countries include major western European pharmaceutical markets like Germany, France, Great Britain, Spain and Italy.
CONTACT
Dr. Thomas Portz
Corporate Communications
Phone +49(0)/78 08-468
thomas.portz@daiichi-sankyo.eu
Olaf Lamberz
Corporate Communications
Phone +49(0)/78 08-442
olaf.lamberz@daiichi-sankyo.eu
Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO EUROPE GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO EUROPE GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
